Investigating Acquisition of Sage Therapeutics by Supernus

Rowley Law PLLC Investigates Securities Law Violations
Rowley Law PLLC is conducting an investigation into potential securities law violations connected to Sage Therapeutics, Inc. (NASDAQ: SAGE) and its board regarding the proposed acquisition by Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). As part of this proposed deal, stockholders are set to receive $8.50 per share along with a contingent value right that may offer up to an additional $3.50 for each share they own.
Details of the Proposed Acquisition
The transaction is being valued at between $561 million and $795 million. It is anticipated that the closure of this acquisition will take place in the third quarter of the upcoming year. This significant financial move is drawing considerable attention from investors and analysts alike as it could reshape the market standing of Sage Therapeutics.
What Stockholders Should Know
If you are a shareholder of Sage Therapeutics, Inc., understanding the implications of this acquisition is essential. Rowley Law PLLC is providing insights and assistance for those seeking more information about the investigation. Those interested can explore further details on the law firm's dedicated investigation webpage.
Legal Representation for Shareholders
Rowley Law PLLC specializes in representing shareholders throughout the nation in class actions and derivative lawsuits. With a commitment to complex corporate litigation, the firm’s expertise can be invaluable during such transactions.
How to Contact Rowley Law PLLC
For interested shareholders looking for more information on the investigation, they are encouraged to reach out directly. The law office is located at 50 Main Street Suite 1000, White Plains, NY 10606. You can also make a call to 914-400-1920 or 844-400-4643 (toll-free) for inquiries.
Learning More About the Law Firm
Potential claimants can get acquainted with Rowley Law PLLC through their website to understand their services and the team’s approach to legal representation. The firm offers guidance and support for anyone navigating securities law issues.
Frequently Asked Questions
What is the proposed acquisition involving Sage Therapeutics?
The acquisition proposed by Supernus Pharmaceuticals aims to acquire Sage Therapeutics, which includes a payment structure for shareholders.
What should shareholders do during this investigation?
Shareholders should stay informed and consider reaching out to legal representation for guidance during the acquisition process.
What type of legal actions does Rowley Law PLLC handle?
Rowley Law PLLC manages class actions and derivative lawsuits, addressing complex corporate litigation on behalf of shareholders.
Where can I find more information about Rowley Law PLLC?
More details about the firm and its services can be found on their official website.
How to contact Rowley Law PLLC for inquiries?
Interested parties can reach the firm via phone or visit their office directly for consultations and inquiries.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.